About Evotec SE
Evotec SE (FWB: EVT) is a biotechnology company engaged in the discovery and clinical development of small-molecule drugs. It provides services for drug discovery, biotherapeutics, Evotec gene therapy, pre-clinical treatment, and chemistry manufacturing and control (CMC). The company was founded in 1993 and is based in Hamburg, Germany.
Evotec SE Patents
Evotec SE has filed 34 patents.
Clusters of differentiation, Immune system, Immunology, Transcription factors, Cytokines
Clusters of differentiation, Immune system, Immunology, Transcription factors, Cytokines
Latest Evotec SE News
Jul 12, 2023
Organisation > EVOTEC AND BRISTOL MYERS SQUIBB ENTER EXCLUSIVE GLOBAL LICENCE AGREEMENT FOR SELECTED PROGRAMMES DEVELOPED AND PROGRESSED IN THE COLLABORATION > SELECTED PROGRAMMES FURTHER STRENGTHEN THE PROGRAMME PIPELINE OF NEURODEGENERATION ASSETS > EVOTEC RECEIVES $ 40 M PAYMENT AND IS ELIGIBLE TO EARN PERFORMANCE MILESTONE PAYMENTS, AS WELL AS TIERED ROYALTIES UP TO LOW DOUBLE-DIGIT PERCENTAGES ON PRODUCT SALES Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that Bristol Myers Squibb Company (NYSE:BMY) has exercised its option to enter into an exclusive global licence agreement. The licence covers selected late-stage discovery programmes that were developed and progressed within the collaboration. Evotec and Bristol Myers Squibb originally entered their neurodegeneration partnership in 2016. The initial partnership proved highly productive in generating a promising pipeline of discovery to clinical-stage programmes. Based on this success, Bristol Myers Squibb and Evotec have extended and expanded the partnership for an additional 8 years in March to further broaden and deepen the strategic alliance. Under the licence agreement, Bristol Myers Squibb has selected an undisclosed number of programmes that were rapidly developed and progressed using Evotecs precision medicine platforms for further development within the expanded collaboration. Evotec receives a $ 40 m payment and is eligible to earn performance milestone payments, as well as tiered royalties up to low double-digit percentages on product sales. Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: This licence agreement will further bolster our joint pipeline of programmes targeting several neurodegenerative conditions. We are confident that the strong collaboration of the experienced teams at Evotec and Bristol Myers Squibb will make novel innovative treatment options available to patients living with a broad range of neurodegenerative conditions. Evotec and Bristol Myers Squibb aim to identify disease-modifying treatments for a broad range of neurodegenerative diseases. Currently approved drugs only offer short-term management of patients symptoms and there is a significant unmet medical need for therapies that slow down or reverse disease progression in the field of neurodegenerative diseases. This partnership pursues an innovative approach to the discovery and development of novel medicines by leveraging several of Evotecs modality-agnostic precision medicine platforms. The partnership has already been successful in generating a pipeline of discovery and pre-clinical-stage programmes. A first programme, BMS-986419 or EVT8683, targeting eIF2b, was in-licensed by Bristol Myers Squibb in September 2021, following the successful filing of an IND application with the FDA and has proceeded into the clinical Phase I. ABOUT EVOTEC SE Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Companys multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this Data-driven R&D Autobahn to Cures for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,900 highly qualified people. The Companys 17 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on Twitter @Evotec and LinkedIn. FORWARD-LOOKING STATEMENTS This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotecs securities. Words such as anticipate, believe, could, estimate, expect, intend, may, might, plan, potential, should, target, would and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotecs expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotecs expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Media Contact Evotec SE: Hinnerk Rohwedder, Director of Global Corporate Communications, Hinnerk.Rohwedder@evotec.com IR Contact Evotec SE:
Evotec SE Frequently Asked Questions (FAQ)
When was Evotec SE founded?
Evotec SE was founded in 1993.
Where is Evotec SE's headquarters?
Evotec SE's headquarters is located at Essener Bogen 7, Hamburg.
What is Evotec SE's latest funding round?
Evotec SE's latest funding round is Corporate Minority - P2P.
Who are the investors of Evotec SE?
Investors of Evotec SE include Bristol Myers Squibb, Novo Holdings, Mubadala Investment Company and Gimv.
Who are Evotec SE's competitors?
Competitors of Evotec SE include Integral Molecular, Arctoris, Arena Pharmaceuticals, AbCellera, Radyus, Embera NeuroTherapeutics, Oxford BioTherapeutics, Hydra Biosciences, Actinobac Biomed, Auspex Pharmaceuticals and 25 more.
Compare Evotec SE to Competitors
The company is engaged in developing and commercializing drugs for the hospital-based treatment of central nervous system (CNS) disorders and thrombotic/cardiovascular diseases, indications for which there is a substantial unmet medical need.
Can-Fite BioPharma is a biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities.
Integral Molecular is a biotechnology company. It develops a pipeline of therapeutic antibodies for membrane protein targets, including GPCRs, ion channels, and transporters. It specializes in optimizing membrane proteins, enabling the isolation, characterization, and engineering of monoclonal antibodies against otherwise intractable membrane protein targets. It serves pharmaceutical and biotechnology companies. The company was founded in 2001 and is based in Philadelphia, Pennsylvania.
Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.
FGI, based in Rockville, Maryland, is developing drugs and diagnostics based on its genome-wide discovery and validation of genes and their roles in human disease. FGI has validated drug candidates for the treatment of infectious disease, drug resistant cancer and Alzheimer's disease.
Richwood develops drugs for disorders of the central nervous system, particularly hyperactivity in children.